FLT3 and acute myeloid leukemia: Relapsed/refractory FLT3‐ITD AML with (24%) or without HCTAged ≥18 y (4% ≥75 y)Cytogenetics: favorable (5%), intermediate (74%), or unfavorable risk (10%)ECOG PS ≤2Adequate hepatic and renal function (bilirubin and creatinine ≤1.5 × ULN, LFTs ≤2.5 × ULN)